News

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

The proprietary AI-Immunology™ platform brings the potential for a new era in vaccine discovery, design and development using advanced AI…

4 months ago

Repligen Appoints Maggie A. Pax to Board of Directors

WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors…

4 months ago

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting…

4 months ago

Kraig Biocraft Laboratories Brings Leading Sericulture Expert from India for Launch of Spring Production Trials

ANN ARBOR, Mich., March 19, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"),…

4 months ago

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

PHILADELPHIA, March 19, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell…

4 months ago

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder

NEW YORK, March 19, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel…

4 months ago

LSL Pharma Group Secures $6.44 Million as the First Closing of Concurrent Non-Brokered Private Placements

$2.7M cash investments secured including $0.4M from Insiders $3.75M of Debt converted BOUCHERVILLE, Quebec, March 19, 2024 (GLOBE NEWSWIRE) --…

4 months ago

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

– Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan,…

4 months ago

Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…

4 months ago

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit’s commitment to strengthening and…

4 months ago